Union européenne - français - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Union européenne - français - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Union européenne - français - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabète sucré, type 2 - les médicaments utilisés dans le diabète - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 et 5. 1 pour les données disponibles sur différentes combinaisons).

Union européenne - français - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - metformini hydrochloridum - comprimés pelliculés - metformini hydrochloridum 500 mg, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, macrogolum 400, e 171 pro compresso obducto. - antidiabétique oral utilisé - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - metformini hydrochloridum - comprimés pelliculés - metformini hydrochloridum 850 mg, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, macrogolum 400, e 171 pro compresso obducto. - antidiabétique oral utilisé - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - metformini hydrochloridum - comprimés pelliculés - metformini hydrochloridum 1000 mg, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, macrogolum 400, e 171 pro compresso obducto. - antidiabétique oral utilisé - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - metformini hydrochloridum - comprimés pelliculés - metformini hydrochloridum 500 mg, magnesii stearas, povidonum k 90, povidonum k 30, Überzug: hypromellosum, e 171, macrogolum 400, pro compresso obducto. - antidiabetikum - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - metformini hydrochloridum - comprimés pelliculés - metformini hydrochloridum 850 mg, magnesii stearas, povidonum k 90, povidonum k 30, Überzug: hypromellosum, e 171, macrogolum 400, pro compresso obducto. - antidiabetikum - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - metformini hydrochloridum - comprimés pelliculés - metformini hydrochloridum 1000 mg, magnesii stearas, povidonum k 90, povidonum k 30, Überzug: hypromellosum, e 171, macrogolum 400, pro compresso obducto. - antidiabetikum - synthetika